| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Department of Cell Cycle and Cancer and 2 Apoptosis Laboratory, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
The human checkpoint kinase Chk1 has been suggested as a target for cancer treatment. Here, we show that a new inhibitor of Chk1 kinase, CEP-3891, efficiently abrogates both the ionizing radiation (IR)-induced S and G2 checkpoints. When the checkpoints were abrogated by CEP-3891, the majority (64%) of cells showed fragmented nuclei at 24 hours after IR (6 Gy). The formation of nuclear fragmentation in IR-treated human cancer cells was directly visualized by time-lapse video microscopy of U2-OS cells expressing a green fluorescent protein-tagged histone H2B protein. Nuclear fragmentation occurred as a result of defective chromosome segregation when irradiated cells entered their first mitosis, either prematurely without S and G2 checkpoint arrest in the presence of CEP-3891 or after a prolonged S and G2 checkpoint arrest in the absence of CEP-3891. The nuclear fragmentation was clearly distinguishable from apoptosis because caspase activity and nuclear condensation were not induced. Finally, CEP-3891 not only accelerated IR-induced nuclear fragmentation, it also increased the overall cell killing after IR as measured in clonogenic survival assays. These results demonstrate that transient Chk1 inhibition by CEP-3891 allows premature mitotic entry of irradiated cells, thereby leading to accelerated onset of mitotic nuclear fragmentation and increased cell death.
This article has been cited by other articles:
![]() |
M. S. Luijsterburg, C. Dinant, H. Lans, J. Stap, E. Wiernasz, S. Lagerwerf, D. O. Warmerdam, M. Lindh, M. C. Brink, J. W. Dobrucki, et al. Heterochromatin protein 1 is recruited to various types of DNA damage J. Cell Biol., May 18, 2009; 185(4): 577 - 586. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Chung, A. P. Brown, H. Asano, M. Mandler, W. E. Burgan, D. Carter, K. Camphausen, and D. Citrin In vitro and In vivo Radiosensitization with AZD6244 (ARRY-142886), an Inhibitor of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase 1/2 Kinase Clin. Cancer Res., May 1, 2009; 15(9): 3050 - 3057. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. R. Danielsen, D. H. Larsen, K. B. Schou, R. Freire, J. Falck, J. Bartek, and J. Lukas HCLK2 Is Required for Activity of the DNA Damage Response Kinase ATR J. Biol. Chem., February 13, 2009; 284(7): 4140 - 4147. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Leonard, H. Ye, C. Wetmore, and L. M. Karnitz Sonic Hedgehog signaling impairs ionizing radiation-induced checkpoint activation and induces genomic instability J. Cell Biol., November 3, 2008; 183(3): 385 - 391. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Morgan, L. A. Parsels, J. Maybaum, and T. S. Lawrence Improving Gemcitabine-Mediated Radiosensitization Using Molecularly Targeted Therapy: A Review Clin. Cancer Res., November 1, 2008; 14(21): 6744 - 6750. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Rebacz, T. O. Larsen, M. H. Clausen, M. H. Ronnest, H. Loffler, A. D. Ho, and A. Kramer Identification of Griseofulvin as an Inhibitor of Centrosomal Clustering in a Phenotype-Based Screen Cancer Res., July 1, 2007; 67(13): 6342 - 6350. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Tse, R. Carvajal, and G. K. Schwartz Targeting Checkpoint Kinase 1 in Cancer Therapeutics Clin. Cancer Res., April 1, 2007; 13(7): 1955 - 1960. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Carlessi, G. Buscemi, G. Larson, Z. Hong, J. Z. Wu, and D. Delia Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2 Mol. Cancer Ther., March 1, 2007; 6(3): 935 - 944. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Tse, K. G. Rendahl, T. Sheikh, H. Cheema, K. Aardalen, M. Embry, S. Ma, E. J. Moler, Z. J. Ni, D. E. Lopes de Menezes, et al. CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo Clin. Cancer Res., January 15, 2007; 13(2): 591 - 602. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Syljuasen, S. Jensen, J. Bartek, and J. Lukas Adaptation to the Ionizing Radiation-Induced G2 Checkpoint Occurs in Human Cells and Depends on Checkpoint Kinase 1 and Polo-like Kinase 1 Kinases Cancer Res., November 1, 2006; 66(21): 10253 - 10257. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Liu, S. Bekker-Jensen, N. Mailand, C. Lukas, J. Bartek, and J. Lukas Claspin Operates Downstream of TopBP1 To Direct ATR Signaling towards Chk1 Activation. Mol. Cell. Biol., August 1, 2006; 26(16): 6056 - 6064. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Lord, M. D. Garrett, and A. Ashworth Targeting the Double-Strand DNA Break Repair Pathway as a Therapeutic Strategy Clin. Cancer Res., August 1, 2006; 12(15): 4463 - 4468. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bekker-Jensen, C. Lukas, R. Kitagawa, F. Melander, M. B. Kastan, J. Bartek, and J. Lukas Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks J. Cell Biol., April 24, 2006; 173(2): 195 - 206. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Ricci and W.-X. Zong Chemotherapeutic approaches for targeting cell death pathways. Oncologist, April 1, 2006; 11(4): 342 - 357. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Sampath, J. Cortes, Z. Estrov, M. Du, Z. Shi, M. Andreeff, V. Gandhi, and W. Plunkett Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial Blood, March 15, 2006; 107(6): 2517 - 2524. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bekker-Jensen, C. Lukas, F. Melander, J. Bartek, and J. Lukas Dynamic assembly and sustained retention of 53BP1 at the sites of DNA damage are controlled by Mdc1/NFBD1 J. Cell Biol., July 18, 2005; 170(2): 201 - 211. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Syljuasen, C. S. Sorensen, L. T. Hansen, K. Fugger, C. Lundin, F. Johansson, T. Helleday, M. Sehested, J. Lukas, and J. Bartek Inhibition of Human Chk1 Causes Increased Initiation of DNA Replication, Phosphorylation of ATR Targets, and DNA Breakage Mol. Cell. Biol., May 1, 2005; 25(9): 3553 - 3562. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Karnitz and S. J. H. Arlander Chk1, a Novel Target to Sensitize Tumor Cells to Replication Inhibitors Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 254 - 257. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |